PRO 231
Alternative Names: PRO-231Latest Information Update: 10 May 2024
At a glance
- Originator Laboratorios Sophia
- Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Conjunctivitis
Most Recent Events
- 30 Jan 2024 Phase-I clinical trials in Conjunctivitis (In volunteers) in Mexico (Ophthalmic) (NCT06363292)